224 related articles for article (PubMed ID: 12756208)
21. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes.
Dennison JB; Jones DR; Renbarger JL; Hall SD
J Pharmacol Exp Ther; 2007 May; 321(2):553-63. PubMed ID: 17272675
[TBL] [Abstract][Full Text] [Related]
22. Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver.
Watanabe M; Kumai T; Matsumoto N; Tanaka M; Suzuki S; Satoh T; Kobayashi S
J Pharmacol Sci; 2004 Apr; 94(4):459-62. PubMed ID: 15107587
[TBL] [Abstract][Full Text] [Related]
23. Induction of cytochrome P450 3A by paclitaxel in mice: pivotal role of the nuclear xenobiotic receptor, pregnane X receptor.
Nallani SC; Goodwin B; Maglich JM; Buckley DJ; Buckley AR; Desai PB
Drug Metab Dispos; 2003 May; 31(5):681-4. PubMed ID: 12695359
[TBL] [Abstract][Full Text] [Related]
24. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43.
Krusekopf S; Roots I; Kleeberg U
Eur J Pharmacol; 2003 Apr; 466(1-2):7-12. PubMed ID: 12679136
[TBL] [Abstract][Full Text] [Related]
25. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.
Mirghani RA; Sayi J; Aklillu E; Allqvist A; Jande M; Wennerholm A; Eriksen J; Herben VM; Jones BC; Gustafsson LL; Bertilsson L
Pharmacogenet Genomics; 2006 Sep; 16(9):637-45. PubMed ID: 16906018
[TBL] [Abstract][Full Text] [Related]
26. Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels.
Chang TK; Bandiera SM; Chen J
Drug Metab Dispos; 2003 Jan; 31(1):7-10. PubMed ID: 12485946
[TBL] [Abstract][Full Text] [Related]
27. Comparison of steroid hormone hydroxylation mediated by cytochrome P450 3A subfamilies.
Niwa T; Okamoto A; Narita K; Toyota M; Kato K; Kobayashi K; Sasaki S
Arch Biochem Biophys; 2020 Mar; 682():108283. PubMed ID: 32001245
[TBL] [Abstract][Full Text] [Related]
28. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
Huang W; Lin YS; McConn DJ; Calamia JC; Totah RA; Isoherranen N; Glodowski M; Thummel KE
Drug Metab Dispos; 2004 Dec; 32(12):1434-45. PubMed ID: 15383492
[TBL] [Abstract][Full Text] [Related]
29. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele.
Sim SC; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Pharmacogenet Genomics; 2005 Sep; 15(9):625-31. PubMed ID: 16041241
[TBL] [Abstract][Full Text] [Related]
30. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers.
RodrÃguez-Antona C; Jande M; Rane A; Ingelman-Sundberg M
Clin Pharmacol Ther; 2005 Apr; 77(4):259-70. PubMed ID: 15903124
[TBL] [Abstract][Full Text] [Related]
31. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression.
Li T; Chiang JY
Drug Metab Dispos; 2006 May; 34(5):756-64. PubMed ID: 16455805
[TBL] [Abstract][Full Text] [Related]
32. Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.
Galetin A; Brown C; Hallifax D; Ito K; Houston JB
Drug Metab Dispos; 2004 Dec; 32(12):1411-20. PubMed ID: 15342470
[TBL] [Abstract][Full Text] [Related]
33. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity.
Kolwankar D; Vuppalanchi R; Ethell B; Jones DR; Wrighton SA; Hall SD; Chalasani N
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):388-93. PubMed ID: 17368239
[TBL] [Abstract][Full Text] [Related]
34. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
Wang YH; Jones DR; Hall SD
Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501
[TBL] [Abstract][Full Text] [Related]
35. Stable overexpression of pregnane X receptor in HepG2 cells increases its potential for bioartificial liver application.
Nibourg GA; Huisman MT; van der Hoeven TV; van Gulik TM; Chamuleau RA; Hoekstra R
Liver Transpl; 2010 Sep; 16(9):1075-85. PubMed ID: 20818746
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells.
Martin P; Riley R; Back DJ; Owen A
Br J Pharmacol; 2008 Feb; 153(4):805-19. PubMed ID: 18037906
[TBL] [Abstract][Full Text] [Related]
37. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
38. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450.
Domanski TL; Finta C; Halpert JR; Zaphiropoulos PG
Mol Pharmacol; 2001 Feb; 59(2):386-92. PubMed ID: 11160876
[TBL] [Abstract][Full Text] [Related]
39. CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes.
Okubo M; Murayama N; Shimizu M; Shimada T; Guengerich FP; Yamazaki H
J Toxicol Sci; 2013; 38(3):349-54. PubMed ID: 23665933
[TBL] [Abstract][Full Text] [Related]
40. Expression and induction of CYP3As in human fetal hepatocytes.
Matsunaga T; Maruyama M; Harada E; Katsuyama Y; Sugihara N; Ise H; Negishi N; Ikeda U; Ohmori S
Biochem Biophys Res Commun; 2004 May; 318(2):428-34. PubMed ID: 15120618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
